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and changes in the 3D sizing guidelines, the new third generation
SAPIEN 3 device can be implanted in the majority of TAVR patients.
Thus, signiﬁcant more TAVR patients can beneﬁt from an aortic valve
replacement with the new SAPIEN 3 device. Within our cohort, im-
plantation of the new SAPIEN 3 device resulted in excellent proce-
dural and short-term outcomes.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) has
been worldwide adopted, but there are still several areas where
consensus and evidence are lacking. Pre-procedural work-up process
is essential to determine eligibility and predict outcomes, but may
vary across centers. The objectives were to determine the real life
practice related to pre-procedural TAVI planning across different
centers around the world.
METHODS From January to May 2015, an online survey was distrib-
uted worldwide in centers performing TAVI regardless the number of
procedures and valve type. There was a responsible to distribute the
survey for each country or region.
RESULTS A total of 167 centers (including 37843 TAVI procedures)
responded the questionnaire from 27 different countries in Europe,
North-America and South-America. Heart team meetings were regu-
larly scheduled in most of the centers (>95%) with high participation
of interventional cardiologist (95%) and cardiac surgeon (94%), but
low involvement of other specialists (radiologists 16%; internists/ge-
riatrics 14%). While one or two surgical risk scores were used in 99%
and 65% of the centers, respectively; frailty (37%), quality of life (23%)
or 6 minute walking (3%) assessments were rarely performed. Mod-
erate or low risk patients represent 20% of the TAVI candidates.
Cardiac-CT was the preferred imaging study for annulus measure-
ments and valve sizing (87%). Finally, concomitant severe coronary
artery disease (CAD) was treated before or during the TAVI procedure
in 79% and 4% of centers, and 3% of centers did not treat systemati-
cally signiﬁcant CAD in TAVI candidates.
CONCLUSIONS In the real-world practice, up to one-ﬁfth of patients
undergoing TAVI are considered at moderate or low surgical risk.
While the role of the Heart Team on the clinical-decision making
process is well established, the involvement of other non-cardiovas-
cular specialists remains anecdotic. Cardiac CT scan is the “gold
standard” for annulus assessment and valve sizing, and signiﬁcant
CAD is treated before the TAVI procedure in the majority of centers.
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BACKGROUND Higher calciﬁcation of the aortic valve complex in-
creases the risk of post-dilatation and paravalvular leak (PVL) after
transcatheter aortic valve replacement (TAVR). The role of aggressive
oversizing as a predictor of PVL post TAVR is not well understood. The
aim of this study was to evaluate the association between degree of
aortic valve complex calciﬁcation and PVL after aggressive oversized
balloon-expandable TAVR.
METHODS Between January 2013 and April 2015, a total of consec-
utive 347 patients with severe aortic stenosis underwent TAVR
(Sapien¼70 or XT¼270) and had suitable contrast cardiac CT.
Aggressive oversizing was deﬁned as over 20% of area oversizing. A
region of interest for calcium volume included the total leaﬂet re-
gion - the area from the annulus to leaﬂet tips and left ventricular
outﬂow tract (LVOT) region- the area from the annulus to 5 mm
inferior to it. Annular device landing zone (ALZ) consisted of the
area from the annulus to 3 mm superior to it and 2 mm inferior to
it. Aortic valve complex was also divided by each leaﬂet sector.
Calcium (CA) scoring was set at 850 Hounsﬁeld Unit threshold. Post
procedural PVL was evaluated by transthoracic echocardiography at
30days.
RESULTS Of 347 patients, aggressive oversizing was performed in133
patients (38.3%). From these patients, 31 patients (23.3%) had
PVL mild (25 patients) or moderate PVL  (6 patients). One patient
had aortic annulus injury. Mean total leaﬂet CA, ALZ CA, and LVOT CA
were 160.9 mm3, 24.2mm3, and 0.4mm3, respectively. ALZ CA, left
coronary cusp (LCC)-ALZ CA, and LCC-LVOT CA were higher in PVL
(41.8  49.7 mm3 vs. 18.9  30.4 mm3; p¼0.02, 22.1  28.8 mm3vs. 8.5
 16.6 mm3; p¼0.016, 17.3  24.3 mm3 vs. 6.0  21.7 mm3; p¼0.025,
respectively). In receiver operator characteristic curve analysis, LVOT
CA and LCC-LVOT CA were predictor of PVL (area under the curve
(AUC) ¼0.739; 95% conﬁdence interval (CI) 0.638-0.840; p <0.001,
AUC¼0.704; 95% CI 0.592-0.816; p¼0.001, respectively).
CONCLUSIONS Of aortic valvular complex calciﬁcation, LVOT volume
was the strongest predictor for PVL after aggressive oversizing
balloon-expandable TAVR.
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BACKGROUND Transcatheter aortic valve replacement (TAVR) en-
ables treatment of inoperable and high risk patients with severe aortic
stenosis. Impact of concomitant mitral regurgitation (MR) on outcome
in patients undergoing TAVR appears to be unclear. Therefore, it was
aim of this study to evaluate the impact of MR on outcome after TAVR.
METHODS Patients with severe aortic stenosis, in which TAVR was
performed between 2006 and 2014 were included into the analysis.
MR was measured by echocardiography at baseline, 30 days and at
one year, 30-day and 1-year mortality was calculated.
RESULTS Between January 2006 and May 2014 a total of 1530
consecutive patients (Age 80.35.9 years, Logistic EuroScore 2013%,
STS PROM 8.56.2%) with severe aortic stenosis were treated with
TAVR at our institution. At baseline 178 (10.3%) of these patients
presented with no MR, 1173 (68.2%) with mild MR (grade 1), 171 (9.9%)
with moderate MR (grade 2) and 9 (0.5%) with severe MR (grade 3).
Patients with moderate to severe MR showed signiﬁcantly higher
